Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations.
The management of the immunosuppression treatment must take account its consequences on viral replication. Such treatment operates on the emerging balance between the recurrence of the virus on the graft and the immune response of the host. Randomized and prospective trials are currently ongoing with the purpose of determining the opportunity and relevance of each immunosuppressive agent in the treatment. In HBV patients, good control of HBV reinfection by prophylactic strategies using HBIG, lamivudine, or both have decreased the impact of immunosuppression on HBV recurrence. In contrast, HCV recurrence is now a major problem. The mechanisms of viral recurrence need to be deepened thus requiring new studies. The absence of in vitro and in vivo systems to study HCV reinfection is a lack in the comprehension of the relation between HCV and immunosuppression. It will allow adapting the effectiveness of the immunosuppression treatment. The treatment's primary target is to avoid graft rejection, and its secondary objective is to limit the risk of viral recurrence.
D006084:Graft Rejection / Q000517:prevention & control; D016174:Hepacivirus / Q000254:growth & development* / Q000276:immunology; D006515:Hepatitis B virus / Q000254:growth & development* / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000601:surgery; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods* / Q000592:standards; D007166:Immunosuppressive Agents / Q000276:immunology / Q000627:therapeutic use; D016031:Liver Transplantation / Q000276:immunology / Q000379:methods*
D007166:Immunosuppressive Agents